Reportable Launches 240-Patient Phase 3 Trial of Huntington’s Therapy After Positive Phase 2 Data

June 2, 2026 -- Reportable announced the initiation of a Phase 3 clinical trial evaluating its investigational therapy for Huntington’s disease (HD), a progressive, inherited neurodegenerative disorder. The study launches on the strength of positive Phase 2 results that showed functional improvements and a strong safety profile, and is intended to confirm efficacy and safety in a larger, global patient population.

“The initiation of our Phase 3 trial represents a significant step forward in our mission to develop transformative medicines for people living with Huntington’s disease,” said Jane Smith, PhD, CEO of Genetic Medicines, Inc. “We believe this program has the potential to meaningfully impact patients and families affected by this devastating condition, and we look forward to advancing the study with urgency and care.”

Key secondary endpoints include Total Functional Capacity (TFC), Total Motor Score (TMS), chorea severity, clinician- and patient-reported global impression scales, and quantitative measures of daily function. Safety assessments will include adverse event monitoring, clinical laboratory tests, ECGs, and neurologic examinations; exploratory biomarkers, such as neurofilament light chain, will also be evaluated.

The Phase 3 design reflects input from investigators, patient advocates, and regulatory discussions, with an emphasis on endpoints that capture clinically meaningful change over 12 months. The study incorporates centralized rater training, standardized imaging where applicable, and predefined statistical methods to control type I error across primary and key secondary outcomes. An independent data monitoring committee will oversee participant safety and study conduct.

“Advancing into Phase 3 is a major achievement for our company and an important moment for the Huntington’s disease community,” said John Doe, MD, CMO of Genetic Medicines, Inc. “We believe this trial brings us closer to delivering a potential disease-modifying therapy for patients in need, and we remain focused on executing the study efficiently and rigorously.”

The program advances based on a previously completed Phase 2 trial in adults with early-manifest HD. In that study, participants receiving the investigational therapy demonstrated improvements in prespecified functional and motor measures compared with placebo at planned time points, and the treatment was well tolerated with an adverse event profile consistent with placebo. These findings informed dose selection, visit schedules, and endpoint prioritization for Phase 3.

Screening is now open, and first patient dosing is expected in Q3 2026. Topline results are anticipated approximately 18 months after the last patient is randomized. The trial will be registered on ClinicalTrials.gov prior to broad enrollment; interested patients and caregivers can speak with their clinicians about eligibility and site participation. Inclusion criteria focus on genetically confirmed HD with early-manifest symptoms and the ability to complete standardized assessments; key exclusions include significant medical comorbidities and recent exposure to investigational agents that could confound outcomes.

Huntington’s disease is caused by a CAG repeat expansion in the HTT gene, leading to progressive neuronal dysfunction and loss. Hallmark features include motor symptoms (chorea and dystonia), cognitive decline, and behavioral changes that intensify over time. There are currently no approved treatments that alter the underlying course of disease, underscoring the need for rigorously tested therapeutic options that can preserve function and quality of life.